Popular Articles
Cellulite Treatment

Illumina Launches Multi-Sample Indexing For GoldenGate(R) Assay
Illumina, Inc. (NASDAQ:ILMN) launched GoldenGate Indexing, a high-throughput genotyping solution that utilizes multi-sample indexing technology. Researchers may now screen up to 16 times as many samples per reaction as the standard GoldenGate Assay, increasing throughput from 288 samples per day to greater than 2000, while decreasing total reagent consumption. This high-quality genotyping system includes automation control and positive sample tracking through an Illumina Laboratory Information Management System (LIMS), creating a turnkey solution for low-complexity screening at an affordable cost per sample. The plexity ranges include 96-plex, 192-plex and 384-plex, which are ideal for screening in the livestock and agriculture market as well as for whole-genome association target validation and quality control applications.
generic viagra online
Possible Genetic Link To Cause Of Pregnancy Loss And Disorders
Scientists at the University of Tennessee, Knoxville, and Lawrence Berkeley National Laboratory (LBNL) have published new findings about a cause of a condition at the root of genetic disorders such as Down Syndrome, pregnancy loss and infertility.
News of the day
Tackling Several Allergens At Once To Prevent Asthma In Kids
Reducing children"s exposure to a variety of allergens, rather than targeting a single "trigger," might be a better way to avoid asthma, according to a new review of studies.
Public Health

First Testicular Cancer Risk Genes Found

A team led by scientists at The Institute of Cancer Research (ICR) compared the genes of 730 men who had developed testicular cancer with the genes of healthy men. They found many of the men who had suffered cancer shared common DNA variants on chromosomes 5, 6 and 12 that the healthy men did not have. Their results mean that men who inherit any of these genetic variants are at a higher risk of developing the disease than those who do not. Inheriting the strongest of the three factors increases men"s risk by two- to threefold, while inheriting all of them increases the risk by up to fourfold. The publication of the research coincides with Everyman Male Cancer Awareness Month in June. This study is an important step towards developing a targeted screening programme for relatives of men who have had testicular cancer. "We have known for some time that men whose father, brothers or sons had testicular cancer are much more likely to get it themselves and we have been searching for this genetic link," one of the lead scientists, Dr Elizabeth Rapley from the ICR, says. "In this research, we have identified three genetic factors linked to an increased risk of testicular cancer. We believe there are more still to be found and we are working on identifying the rest." "The risk conferred by each gene differs, but in one case it is two-to threefold," Professor Mike Stratton from the Wellcome Trust Sanger Institute and the ICR says. "The risks also add together to some extent, so that men who inherit all the risk variants we found are four times more likely than the general population to develop testicular cancer. By combining these genetic risks with other known risk factors it may be possible in future to identify men who are at high risk of developing testicular cancer, particularly those who have a brother or father already affected by the disease. This may allow early detection or prevention." The study - funded by the Everyman Campaign, Cancer Research UK and the Wellcome Trust - has also given researchers a clue to the mechanism by which testicular cancer develops. The three markers were all found near genes involved in the same biochemical pathway - one which is important in the survival and development of germ cells (cells that go on to form sperm). Disrupting this important pathway may be one mechanism by which cancer can grow. "By understanding the biology of this disease we hope to improve treatment options," Dr Rapley says. The researchers are now looking for up to 3000 men who have had testicular cancer to participate in the study to identify more genetic risk factors. These new volunteers would provide a blood sample and fill in a questionnaire. "We are hopeful we can find more risk factors but we do need more people affected by testicular cancer to help in this research," Dr Rapley says. "We are grateful to all those men who have participated in this study so far, and would like anybody who has suffered testicular cancer to contact us - even if they were treated 20 years ago. They could ultimately help us develop treatments and improve diagnostic techniques to improve the lives of sufferers in the future." Men interested in participating in the study can find more information online. Testicular cancer is the most common form of cancer in men aged between 15 and 44, with about 2000 cases a year in the UK. Incidence is increasing dramatically - almost fourfold in the last 50 years - but testicular cancer is 99 per cent curable if caught early, and with treatment the overall cure rate is 97 per cent. Studies have found the risk to brothers of testicular cancer patients to be eight to ten times higher than the general population; while for fathers of sufferers the risk is four to six times higher. These inheritance risk factors are much higher than for other cancer types, which are generally only twofold. The Institute of Cancer Research


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):